NOV 24, 2019 11:38 PM PST

The unlikely pain killer

WRITTEN BY: Nouran Amin

Pain can be anything a sunburn, a toothache, or a leg injury to name a few. The relievers that target our pain come in many colors—one being morphine, a widely used opioid.

Learn more about the biology of pain:

Now, a graduate student at West Virginia University, Shane Kaski, is studying how an anti-itch medication can be effective at relieving pain. Specifically, Kaski is examining how the drug ‘nalfurafine’ targets a certain region of our nerve cells that can make morphine more effective. The research could potentially fight against opioid addiction by making patients less reliant on morphine. Essentially, nalfurafine could serve as a ‘supplement’.

"Right now there's a lot of work looking for replacements for opioids, for obvious reasons," said Kaski, a graduate student in the School of Medicine's M.D./Ph.D. program. "Maybe nalfurafine is not so great as a replacement on its own, but maybe it does enough that we could put it together with other opioids and get this dose-sparing effect."

Using a supplemental dose of nalfurafine along with a decreased dose of morphine was found to reduce as much pain as a large dose of morphine alone. The findings of the study were published in the Journal of Pharmacology and Experimental Therapeutics.

"It's possible that you just need a tiny smidgen of nalfurafine with a smidgen of this other addictive drug to get the equivalent pain relief from a larger dose of your addictive drug," he said. "That's what we're seeing in our early work. That's the promise that we saw."

However, there is a paradox—because to fight the opioid addiction, we use another opioid. Nalfurafine, like morphine, is an opioid. But, how exactly is that supposed to work? The answer to that is through pain receptors.

“Why are you going to use another opioid on top of morphine? It comes down to the specifics of the biology of opioid receptors,” says Kaski. "The biggest three opioid receptors you'll hear about are mu, kappa and delta.”

“Nalfurafine is unusual. Even though it's an opioid, it doesn't have a permit to park in mu. Instead it parks in the kappa receptor. Once it does, it alleviates pain while also "putting the brakes on" the reward circuit that can lead to addiction,” Kaski adds.

Source: West Virginia University

About the Author
  • Nouran earned her BS and MS in Biology at IUPUI and currently shares her love of science by teaching. She enjoys writing on various topics as well including science & medicine, global health, and conservation biology. She hopes through her writing she can make science more engaging and communicable to the general public.
You May Also Like
OCT 11, 2020
Drug Discovery & Development
Treating Connective Tissue Disorders
OCT 11, 2020
Treating Connective Tissue Disorders
Collaborative research efforts are geared to improving disease that affects connective tissues via innovative drug deliv ...
NOV 01, 2020
Cannabis Sciences
Can Cannabis Treat ALS?
NOV 01, 2020
Can Cannabis Treat ALS?
Amyotrophic Lateral Sclerosis (ALS) is a neurodegenerative illness that damages motor neurons and leads to progressive m ...
NOV 05, 2020
Immunology
Awakening Ancient DNA to Kill Cancer
NOV 05, 2020
Awakening Ancient DNA to Kill Cancer
In a recent study published in Nature, scientists from the University of Toronto described the discovery of ancient DNA ...
NOV 06, 2020
Immunology
The Coronavirus Is No Match Against Sybody 23
NOV 06, 2020
The Coronavirus Is No Match Against Sybody 23
The virus that causes COVID-19, SARS-CoV-2, uses its spike protein to gain access to cells, by binding to the ACE2 recep ...
NOV 09, 2020
Drug Discovery & Development
COVID-19 Vaccine by Pfizer More than 90% Effective
NOV 09, 2020
COVID-19 Vaccine by Pfizer More than 90% Effective
A preliminary analysis of Pfizer and BioNTech's COVID-19 vaccine shows that it can prevent over 90% of people from c ...
NOV 20, 2020
Drug Discovery & Development
Cat Parasite Gives Clues on New Drug Targets for Schizophrenia
NOV 20, 2020
Cat Parasite Gives Clues on New Drug Targets for Schizophrenia
Researchers from the UK and France have discussed a mechanism of action behind the infamous Toxoplasma gondii  ...
Loading Comments...